Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: population-based estimates from GLOBOCAN 2022

作者：Kexin Sun, Hongliang Wu, Qian Zhu, Kai Gu, Hui Wei, Shaoming Wang, Li Li, Chunxiao Wu, Ru Chen, Yi Pang, Bingfeng Han, Hongmei Zeng, Meicen Liu, Zheng Rongshou, Wenqiang Wei · 发表于：EClinicalMedicine · 年份：2025 · DOI：10.1016/j.eclinm.2025.103193 · 被引用次数：30 · 研究领域：Acute Lymphoblastic Leukemia research、Global Cancer Incidence and Screening、Economic and Financial Impacts of Cancer

Background: Haematologic malignancies accounted for 6.6% of total cancer cases and 7.2% of total cancer-related deaths worldwide in 2022. We implemented a novel approach to estimate the lifetime risk of developing and dying from various types of haematologic malignancies at the global, regional and country-specific perspectives in 2022. Methods: We retrieved incidence and mortality rates for Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and leukaemia from GLOBOCAN 2022 of 185 countries, along with the national population statistics and all-cause mortality data sourced from the United Nations. For trend analysis, we obtained consecutive cancer registry data spanning from 2003 to 2017 from the Cancer Incidence in Five Continents (CI5) Plus database. After quality control, datasets from 30 countries were included. We used the "adjusted for multiple primaries (AMP)" method to calculate the lifetime risk of incidence (LRI) and mortality (LRM) by cancer type, selected age interval, sex, country and geographic region. Findings: In 2022, the global lifetime risk of incidence (LRI) and mortality (LRM) for all haematologic malignancies was 1.67% and 0.98%, respectively. LRI was highest for NHL, whereas the LRM was highest for leukaemia. On a general level, males exhibited higher LRI and LRM compared to females. Both LRI and LRM increased with higher Human Development Index (HDI) levels. The LRI and LRM for haematologic malignancies were notably high in region...